Skip to main content
OLIPASS CORPORATION logo

OLIPASS CORPORATION — Investor Relations & Filings

Ticker · 244460 ISIN · KR7244460002 KO Professional, scientific and technical activities
Open in API
Filings indexed 507 across all filing types
Latest filing 2021-04-06 Major Shareholding Noti…
Country KR South Korea
Listing KO 244460

About OLIPASS CORPORATION

https://www.olipass.com/front/eng/index…

OLIPASS CORPORATION is a research and development company focused on creating RNA therapeutics. The company's core activities are centered on its proprietary OliPass Peptide Nucleic Acid (OPNA) platform. OPNA is a novel technology derived from Peptide Nucleic Acid (PNA) by introducing a cationic lipid moiety onto the nucleobase. This structural modification is designed to markedly improve cell permeability, a key challenge in nucleic acid-based drug delivery. The platform is optimized to induce exon skipping by specifically binding to target pre-mRNA inside the cell nucleus, enabling the discovery and development of new therapeutic candidates.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the share ownership, changes in holdings, and major contracts (such as collateral agreements) of the company's largest shareholder and their special related parties. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2021-04-06 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 95% confidence The document is a formal announcement regarding the scheduling and logistics of an upcoming Investor Relations (IR) presentation. It provides the date, time, location (online), and purpose of the event. Since it is an announcement of an event rather than the presentation slides themselves, and it serves to notify investors of the upcoming disclosure, it falls under the category of a Report Publication Announcement or general regulatory filing regarding IR activities.
2021-04-06 Korean
기타경영사항(특허권취득)(자율공시)(TYROSINASE ANTISENSE OLIGONUCLEOTIDES)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent (특허권 취득) by the company Olipass. It details the patent name, content, and utilization plan. Since this is a regulatory announcement regarding a specific corporate event that does not fall into the categories of financial reports, management changes, or shareholder meetings, it is classified as a general regulatory filing.
2021-04-05 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a standard Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This document details the share ownership and changes in holdings by a company executive (Kim Hoe-cheon of Olipass Co., Ltd.). This type of filing is specifically categorized as a 'Director's Dealing' (DIRS) report, as it tracks insider transactions and ownership status.
2021-04-02 Korean
기타경영사항(특허권취득)(자율공시)(티로시나아제 안티센스 올리고뉴클레오티드)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent (특허권 취득) by the company Olipass. It details the patent name, content, and utilization plan. Since this is a specific corporate announcement regarding business operations that does not fit into financial reporting, dividend, or governance categories, it falls under the general regulatory filing category.
2021-03-31 Korean
투자판단관련주요경영사항(OLP-1002 비마약성진통제 신약 영국 임상1상 시험결과)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from a Korean company (Olipass) regarding the results of a Phase 1 clinical trial for a drug candidate (OLP-1002). It follows the standard format for 'Major Management Matters' (주요경영사항) filings in Korea, which are used to disclose material events such as clinical trial results. Since it is a formal regulatory disclosure of a specific business event rather than a general report, a financial statement, or a simple announcement of a report, it falls under the 'Regulatory Filings' category.
2021-03-29 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.